{"disease":{"id":"parkinsonian-syndromes","name":"parkinsonian syndromes"},"drugs":{"marketed":[{"drug_id":"fluorodopa","indication_name":"Evaluation of suspected Parkinsonian syndromes","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fluorodopa F18","generic_name":"FLUORODOPA","company_name":"Feinstein","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":38,"revenue":null,"mechanism":""},{"drug_id":"fluorodopa-18f","indication_name":"Evaluation of suspected Parkinsonian syndromes","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fluorodopa F18","generic_name":"fluorodopa (18F)","company_name":"Feinstein","drug_phase":"marketed","molecular_target":"","drug_class":"fluorodopa (18F)","quality_score":31,"revenue":null,"mechanism":""},{"drug_id":"fluorodopa","indication_name":"Parkinsonian syndromes (PS)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fluorodopa F18","generic_name":"FLUORODOPA","company_name":"Feinstein","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":38,"revenue":null,"mechanism":""},{"drug_id":"ioflupane","indication_name":"suspected Parkinsonian syndromes","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ioflupane I 123","generic_name":"IOFLUPANE","company_name":"Ge Hlthcare Inc","drug_phase":"marketed","molecular_target":"Dopamine transporter (DaT)","drug_class":"Radioactive Diagnostic Agent [EPC]","quality_score":70,"revenue":null,"mechanism":"Ioflupane I-123 binds to the dopamine transporter (DaT) in the striatum, allowing visualization of brain striata through SPECT imaging."}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02114242","title":"Biomarkers in Parkinsonian Syndromes","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"University Hospital, Bordeaux","has_results":false},{"nct_id":"NCT06193278","title":"Individual Neuromodulation for PDS","phase":"NA","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Ruijin Hospital","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}